Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    World-Pharmacists-Day-Insert
    X

    Find FDA Investigational New Drug (IND) Submissions for Psychiatry/Psychology in UNITED STATES

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Protagenic Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Natural Products Expo

              Participation Not Confirmed

              Update your events

              Protagenic Therapeutics Completes $2.0 MillionConvertible Note Financing

              Contact the Supplier

              Lead Product(s): PT00114

              Therapeutic Area: Psychiatry/Psychology Product Name: PT00114

              Highest Development Status: IND Enabling Product Type: Peptide

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $2.0 million Upfront Cash: Undisclosed

              Deal Type: Financing September 08, 2020

              Details:

              The capital will be used to complete the last remaining components of the Company’s investigational New Drug (IND) filing with the FDA for its lead drug compound, PT00114, known scientifically as teneurin C-terminal associated peptide (TCAP).

              BioXcel Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Natural Products Expo

              Participation Not Confirmed

              Update your events

              BioXcel Gets FDA Clearance of IND Application for BXCL501

              Contact the Supplier

              Lead Product(s): Dexmedetomidine

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 05, 2020

              Details:

              The FDA clearance of the IND application for opioid withdrawal, is an important step in BioXcel's plans to build a neuroscience franchise around the multiple therapeutic opportunities with BXCL501.

              OWP Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Natural Products Expo

              Participation Not Confirmed

              Update your events

              OWP Pharmaceuticals Announces Pre-IND Acknowledgement and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Quetia...

              Contact the Supplier

              Lead Product(s): Quetiapine Fumarate

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 08, 2020

              Details:

              This acknowledgement represents the third of several oral suspensions in neuroscience that OWP Pharmaceuticals hopes to commercialize over the next several years via a 505(b)(2) application.

              PharmaCompass__DigitalAd